InsiderTrades.com logo
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
From Brownstone Research   |   Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.

SYRE Insider Trading

Insider Ownership Percentage: 6.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $10,929.00

Spyre Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Spyre Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spyre Therapeutics Share Price & Price History

Current Price: $24.07
Price Change: ▲ Price Increase of +0.73 (3.13%)
As of 12/26/2024 05:00 PM ET

This chart shows the closing price history over time for SYRE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Do this Before Elon’s Reveal on January 22nd
From Brownstone Research   |   Ad
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
I urge you to watch this video now.

Spyre Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2024Jeffrey W AlbersDirectorSell300$36.43$10,929.0034,060View SEC Filing Icon  
See Full Table
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing   |   Ad
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry. 

SEC Filings (Institutional Ownership Changes) for Spyre Therapeutics (NASDAQ:SYRE)

80.39% of Spyre Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SYRE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Spyre Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
12/26/2024JPMorgan Chase & Co.29,473$0.87M0.0%+29.4%0.057%Search for SEC Filing on Google Icon
11/27/2024Franklin Resources Inc.760,666$23.32M0.0%+2.5%1.479%Search for SEC Filing on Google Icon
11/18/2024Teachers Retirement System of The State of Kentucky21,154$0.62M0.0%N/A0.041%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC891,048$26.21M0.0%+16.4%1.733%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC105,467$3.10M0.0%+64.7%0.205%Search for SEC Filing on Google Icon
11/15/2024Jane Street Group LLC20,641$0.61M0.0%+78.7%0.040%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP1,507,200$44.33M0.0%+89.4%2.931%Search for SEC Filing on Google Icon
11/15/2024State Street Corp1,541,555$45.34M0.0%+9.4%2.997%Search for SEC Filing on Google Icon
11/15/2024Ikarian Capital LLC302,247$8.89M1.2%N/A0.588%Search for SEC Filing on Google Icon
11/15/2024Janus Henderson Group PLC1,120,531$32.92M0.0%+66.3%2.179%Search for SEC Filing on Google Icon
11/15/2024HighVista Strategies LLC105,351$3.10M1.1%-7.2%0.205%Search for SEC Filing on Google Icon
11/15/2024Cinctive Capital Management LP61,256$1.80M0.1%N/A0.119%Search for SEC Filing on Google Icon
11/14/2024Braidwell LP2,189,836$64.40M1.8%-12.9%4.258%Search for SEC Filing on Google Icon
11/14/2024Walleye Capital LLC243,372$7.16M0.0%+61.4%0.473%Search for SEC Filing on Google Icon
11/14/2024UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC26,441$0.78M0.0%-12.2%0.051%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC20,132$0.59M0.0%+129.1%0.039%Search for SEC Filing on Google Icon
11/13/2024FMR LLC7,623,881$224.22M0.0%+1.5%14.824%Search for SEC Filing on Google Icon
11/13/2024The Manufacturers Life Insurance Company43,460$1.28M0.0%+15.0%0.085%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.333,275$9.80M0.0%+239.4%0.655%Search for SEC Filing on Google Icon
11/9/2024Intech Investment Management LLC8,371$0.25M0.0%N/A0.016%Search for SEC Filing on Google Icon
11/7/2024Quest Partners LLC5,654$0.17M0.0%+271.2%0.011%Search for SEC Filing on Google Icon
10/29/2024Emerald Advisers LLC292,569$8.60M0.3%N/A0.575%Search for SEC Filing on Google Icon
10/29/2024Emerald Mutual Fund Advisers Trust253,550$7.46M0.4%N/A0.498%Search for SEC Filing on Google Icon
10/23/2024Assenagon Asset Management S.A.1,142,768$33.61M0.1%N/A2.837%Search for SEC Filing on Google Icon
10/3/2024SG Americas Securities LLC12,589$0.37M0.0%+127.0%0.031%Search for SEC Filing on Google Icon
8/16/2024Perceptive Advisors LLC3,031,018$71.26M1.7%+18.6%7.524%Search for SEC Filing on Google Icon
8/16/2024Driehaus Capital Management LLC687,080$16.15M0.2%N/A1.706%Search for SEC Filing on Google Icon
8/15/2024The Manufacturers Life Insurance Company37,782$0.89M0.0%N/A0.094%Search for SEC Filing on Google Icon
8/15/2024Darwin Global Management Ltd.452,040$10.27M1.2%N/A1.122%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC136,000$3.20M0.0%N/A0.338%Search for SEC Filing on Google Icon
8/15/2024Affinity Asset Advisors LLC513,420$12.07M1.4%N/A1.275%Search for SEC Filing on Google Icon
8/14/2024Great Point Partners LLC134,612$3.17M0.6%N/A0.334%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP575,000$13.52M1.1%N/A1.427%Search for SEC Filing on Google Icon
8/14/2024Farallon Capital Management LLC666,000$15.66M0.1%N/A1.653%Search for SEC Filing on Google Icon
8/14/2024Integral Health Asset Management LLC100,000$2.35M0.2%N/A0.248%Search for SEC Filing on Google Icon
8/14/2024Avoro Capital Advisors LLC1,839,138$43.24M0.6%N/A4.566%Search for SEC Filing on Google Icon
8/14/2024HighVista Strategies LLC113,550$2.67M1.0%N/A0.282%Search for SEC Filing on Google Icon
8/14/2024Profund Advisors LLC12,606$0.30M0.0%N/A0.031%Search for SEC Filing on Google Icon
8/13/2024Ensign Peak Advisors Inc82,475$1.94M0.0%N/A0.205%Search for SEC Filing on Google Icon
8/12/2024Amalgamated Bank1,198$28K0.0%N/A0.003%Search for SEC Filing on Google Icon
8/9/2024Carlyle Group Inc.9,620$0.23M0.0%N/A0.024%Search for SEC Filing on Google Icon
8/8/2024First Turn Management LLC464,435$10.92M1.8%N/A1.153%Search for SEC Filing on Google Icon
8/6/2024Quest Partners LLC1,523$36K0.0%N/A0.004%Search for SEC Filing on Google Icon
8/6/2024Candriam S.C.A.105,000$2.47M0.0%N/A0.261%Search for SEC Filing on Google Icon
8/3/2024TD Asset Management Inc35,168$0.83M0.0%N/A0.087%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers51,896$1.22M0.0%N/A0.129%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp117,686$2.77M0.0%N/A0.292%Search for SEC Filing on Google Icon
7/26/2024EFG Asset Management North America Corp.36,781$0.87M0.2%N/A0.091%Search for SEC Filing on Google Icon
7/12/2024SG Americas Securities LLC5,545$0.13M0.0%N/A0.014%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Spyre Therapeutics logo
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More on Spyre Therapeutics

Today's Range

Now: $24.07
Low: $22.95
High: $24.08

50 Day Range

MA: $29.77
Low: $23.13
High: $39.58

52 Week Range

Now: $24.07
Low: $18.54
High: $47.97

Volume

285,032 shs

Average Volume

526,820 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82

Who are the company insiders with the largest holdings of Spyre Therapeutics?

Spyre Therapeutics' top insider shareholders include:
  1. Jeffrey W Albers (Director)
Learn More about top insider investors at Spyre Therapeutics.

Who are the major institutional investors of Spyre Therapeutics?

Spyre Therapeutics' top institutional shareholders include:
  1. FMR LLC — 14.82%
  2. Braidwell LP — 4.26%
  3. State Street Corp — 3.00%
  4. Wellington Management Group LLP — 2.93%
  5. Assenagon Asset Management S.A. — 2.84%
  6. Janus Henderson Group PLC — 2.18%
Learn More about top institutional investors of Spyre Therapeutics stock.

Which institutional investors are selling Spyre Therapeutics stock?

In the last quarter, SYRE stock was sold by these institutional investors:
  1. Braidwell LP
  2. HighVista Strategies LLC
  3. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Which institutional investors are buying Spyre Therapeutics stock?

In the last quarter, SYRE stock was bought by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. Wellington Management Group LLP
  3. Janus Henderson Group PLC
  4. Ikarian Capital LLC
  5. Emerald Advisers LLC
  6. Emerald Mutual Fund Advisers Trust
  7. Charles Schwab Investment Management Inc.
  8. State Street Corp
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
From Brownstone Research   |   Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.